361 completed, 145 terminated, 100 recruiting, 84 unknown. 815 Phase 2, 214 Phase 1, 6 Phase 3.
Follow Carcinoma, Renal Cell: new trials by email Literature Review of Carcinoma, Renal Cell trials Research Report on Carcinoma, Renal Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 30 | 2026-12-01 | 2026-10-26 |
| A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread Envafolimab+Lenvatinib - Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2026-09-09 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab - Renal Cell Carcinoma, Clear Cell | Phase 2 | Not yet recruiting | Summit Therapeutics | 100 | 2026-10-19 | 2026-10-16 |
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-09-20 | 2026-09-14 |
| CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC 89Zr-Girentuximab - Clear Cell Renal Cell Carcinoma (ccRCC), ccRCC | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 10 | 2026-09-16 | 2026-07-21 |
| Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA 5-Aminolevulinic acid Hydrochloride (Gliolan®) - Kidney Cancers | Phase 2 | Recruiting | Henry Ford Health System | 10 | 2026-09-15 | 2026-09-18 |
| Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 31 | 2026-08-28 | 2026-10-23 |
| TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-08-20 | 2026-08-20 |
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial Ipilimumab Injection, Sintilimab injection, Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Immunotherapy | Phase 2 | Not yet recruiting | West China Hospital | 66 | 2026-08-01 | 2026-07-20 |
| Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment Pembrolizumab 200 mg Q3W, Lenvatinib 20mg QD - ccRCC | Phase 2 | Not yet recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 108 | 2026-08-01 | 2026-03-10 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 265 | 2026-07-20 | 2026-09-28 |
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | VM Discovery, Inc. | 111 | 2026-07-16 | 2026-08-19 |
Showing 20 of 815. Sign in to see all of them.
Kidney Neoplasms (222) · Melanoma (105) · Carcinoma, Non-Small-Cell Lung (93) · Neoplasm Metastasis (88) · Neoplasms (47) · Colorectal Neoplasms (41) · Carcinoma, Hepatocellular (37) · Squamous Cell Carcinoma of Head and Neck (36) · Carcinoma, Transitional Cell (34) · Stomach Neoplasms (33) · Uterine Cervical Neoplasms (31) · Triple Negative Breast Neoplasms (30) · Breast Neoplasms (29) · Ovarian Neoplasms (29)
Female Urogenital Diseases (815) · Female Urogenital Diseases and Pregnancy Complications (815) · Male Urogenital Diseases (815) · Urogenital Diseases (815) · Urologic Diseases (814) · Neoplasms by Histologic Type (813) · Neoplasms, Glandular and Epithelial (813) · Kidney Diseases (812) · Neoplasms by Site (811) · Adenocarcinoma (810) · Urogenital Neoplasms (809) · Urologic Neoplasms (806) · Carcinoma (798) · Neoplasms (768) · Kidney Neoplasms (593)
Nivolumab (86) · Sunitinib (74) · pembrolizumab (72) · Bevacizumab (48) · Axitinib (45) · Sorafenib (43) · Everolimus (36) · Ipilimumab (35) · cabozantinib (35) · aldesleukin (33) · pazopanib (27) · Interleukin-2 (26) · lenvatinib (23) · Interferon-alpha (20) · Magnetic Resonance Spectroscopy (20)
National Cancer Institute (NCI) (73) · M.D. Anderson Cancer Center (37) · Memorial Sloan Kettering Cancer Center (19) · Pfizer (13) · Bayer (10) · Case Comprehensive Cancer Center (10) · Merck Sharp & Dohme LLC (10) · Novartis Pharmaceuticals (10) · City of Hope Medical Center (8) · Jonsson Comprehensive Cancer Center (8) · Bristol-Myers Squibb (7) · Hoffmann-La Roche (7) · Kidney Cancer Research Bureau (7) · Sun Yat-sen University (7) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (6)
United States (519) · China (76) · United Kingdom (69) · France (60) · Canada (55) · Spain (52) · Australia (48) · Italy (45) · Germany (40) · South Korea (38) · Netherlands (31) · Poland (25) · Belgium (22) · Russia (18) · Czechia (16)
Eric Jonasch, MD (12) · Giuseppe Procopio, MD (7) · Robert J. Motzer, MD (6) · Robert J Amato, DO (5) · Brian I. Rini, MD (4) · Brian Rini (4) · Eric Jonasch (4) · Walter Stadler (4)
PMID 37146227, PMID 27238653, PMID 28410911, PMID 25577718, PMID 32499241, PMID 22980441, PMID 23964934, PMID 25532471, PMID 26706103, PMID 31401903, PMID 35420628, PMID 36848607, PMID 39462179, PMID 41969229, PMID 10751849, PMID 10984562, PMID 11282341, PMID 11698646, PMID 11743264, PMID 12419754, PMID 12890838, PMID 14555767, PMID 14581348, PMID 14685170, PMID 15076283, PMID 15744595, PMID 15771580, PMID 15791454, PMID 15800326, PMID 16127434, PMID 16222691, PMID 16227604, PMID 16314647, PMID 16706633, PMID 16757724, PMID 16785067, PMID 16832603, PMID 16859580, PMID 16909426, PMID 16982775, PMID 17393073, PMID 17437788, PMID 17474988, PMID 17876014, PMID 17893567, PMID 17928952, PMID 17951335, PMID 18157014, PMID 18161005, PMID 18230058
2016 (9), 2023 (9), P30CA033572 (9), P30CA043703 (8), 2008 (7), 2015 (6), 2018 (6), P30CA016672 (6), U10CA032102 (6), P30CA015704 (5), 2017 (4), 2019 (4), 2025 (4), U10CA021115 (4), U10CA031946 (4)